#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3756	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2436	458.1	0	.	n	.	0	C1450T	SNP	1450	1450	C	1848	1848	T	506	T	457	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	3756	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2436	458.1	1	SNP	n	C1184T	0	.	.	1184	1184	C	1582	1582	C	507	C	439	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6006	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3864	466.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1843	1843	A	464	A	416	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6006	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3864	466.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2477	2477	C	566	C	493	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6006	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3864	466.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2551	2551	A	590	A,C	502,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	6006	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3864	466.1	1	SNP	n	C2597T	0	.	.	2597	2597	C	3103	3103	C	528	C,A	448,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	646	folP	852	852	99.88	folP.l6.c17.ctg.1	1784	108.6	0	.	p	.	0	P68S	NONSYN	202	204	CCG	665	667	TCG	149;150;151	T;C;G	123;125;123	.	.
folP.WHO_F_01537c	folP.WHO_F_01537c	1	1	539	646	folP	852	852	99.88	folP.l6.c17.ctg.1	1784	108.6	1	SNP	p	R228S	0	.	.	682	684	CGC	1145	1147	CGC	146;146;146	C;G;C	131;132;130	folP.WHO_F_01537c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1266	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3805	99.8	1	SNP	p	S91F	0	.	.	271	273	TCC	786	788	TCC	78;80;80	T;C;C	69;71;71	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1266	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3805	99.8	1	SNP	p	D95N	0	.	.	283	285	GAC	798	800	GAC	80;80;80	G;A;C	72;71;72	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1266	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3805	99.8	1	SNP	p	D95G	0	.	.	283	285	GAC	798	800	GAC	80;80;80	G;A;C	72;71;72	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	468	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1690	83.2	0	.	p	.	0	A39T	NONSYN	115	117	GCC	636	638	ACC	131;131;131	A,G;C;C	112,1;115;115	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	468	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1690	83.2	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	834	836	CAC	128;128;127	C,T;A;C	105,2;108;106	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	468	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1690	83.2	0	.	p	.	0	E117K	NONSYN	349	351	GAA	870	872	AAA	129;128;129	A,G;A;A	106,1;106;106	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	468	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1690	83.2	1	SNP	p	G45D	0	.	.	133	135	GGC	654	656	GGC	131;130;130	G;G;C	113;114;112	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	340	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1241	82.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1254	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3260	115.4	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1646	1648	ATC	133;133;132	A;T;C	112;113;110	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1254	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3260	115.4	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1799	1801	GCA	134;134;134	G,A,T;C,T;A	113,1,1;115,1;113	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1254	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3260	115.4	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2282	2284	ATT	148;148;148	A;T;T	120;118;119	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1254	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3260	115.4	1	SNP	p	D86N	0	.	.	256	258	GAC	752	754	GAC	152;152;152	G;A;C	127;126;130	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1254	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3260	115.4	1	SNP	p	S87W	0	.	.	259	261	AGT	755	757	AGT	153;155;155	A;G;T	127;133;130	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1254	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3260	115.4	1	SNP	p	S87R	0	.	.	259	261	AGT	755	757	AGT	153;155;155	A;G;T	127;133;130	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1254	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3260	115.4	1	SNP	p	S87I	0	.	.	259	261	AGT	755	757	AGT	153;155;155	A;G;T	127;133;130	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	1254	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3260	115.4	1	SNP	p	S88P	0	.	.	262	264	TCC	758	760	TCC	155;156;156	T;C;C	132;135;133	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1078	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3033	106.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1769	1771	GGC	140;140;140	G;G;C	114;116;114	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	1048	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2759	113.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1431	1433	GCA	177;178;180	G;C;A	149;149;147	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1048	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2759	113.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1434	1436	ATC	179;179;178	A;T;C,A	150;147;148,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1048	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2759	113.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1446	1448	GTG	180;179;180	G;T;G	146;147;146	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1048	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2759	113.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1446	1448	GTG	180;179;180	G;T;G	146;147;146	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1048	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2759	113.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1950	1952	ACC	133;133;133	A;C;C	119;116;120	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1048	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2759	113.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2004	2006	GCG	133;133;133	G;C,G;G	111;90,1;102	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1048	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2759	113.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2004	2006	GCG	133;133;133	G;C,G;G	111;90,1;102	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1048	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2759	113.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2127	2129	GGT	128;128;128	G;G;T	104;105;100	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1048	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2759	113.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2136	2138	GGC	127;128;128	G;G;C	109;107;102	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	1048	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2759	113.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2154	2156	CCG	126;127;126	C;C;G	97;103;104	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	27	1356	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3392	120.0	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1752	1754	CTG	112;113;114	C,T;T;G	94,1;91;92	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	642	porA	1146	1146	99.65	porA.l15.c4.ctg.1	2070	92.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	653	653	C	101	C	92	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	836	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	1889	131.9	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	921	923	CAA	190;186;188	C,T;A;A	156,1;158;157	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	836	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	1889	131.9	0	.	p	.	0	E212G	NONSYN	634	636	GAA	1128	1130	GGT	177;177;178	G;G;T	156;157;158	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	836	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	1889	131.9	0	.	p	.	0	H213G	NONSYN	637	639	CAT	1131	1133	GGT	178;177;177	G;G;T	157;156;155	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	836	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	1889	131.9	0	.	p	.	0	V215D	NONSYN	643	645	GTT	1137	1139	GAT	178;178;178	G;A;T	158;156;159	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	836	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	1889	131.9	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1146	1148	ATG	181;180;181	A;T;G,A	154;157;157,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	836	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	1889	131.9	0	.	p	.	0	R257K	NONSYN	769	771	AGG	1263	1265	AAG	158;158;158	A;A;G	138;139;139	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	836	porB1b	1047	1047	98.95	porB1b.l15.c4.ctg.1	1889	131.9	1	SNP	p	G120K	0	.	.	358	360	GGC	852	854	GGC	192;193;192	G,A;G;C,T	157,1;157;155,1	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	2512	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	5186	145.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2146	2148	CAT	168;167;166	C,T;A;T,A	148,1;151;148,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	398	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1309	91.0	1	SNP	p	V57M	0	.	.	169	171	GTG	650	652	GTG	160;158;159	G,T;T,G;G	135,1;134,1;135	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
